Strong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1. by Dyer, W, Ogg, G, Demoitie, M, Jin, X, Geczy, A, Rowland-Jones, S, Mcmichael, A, Nixon, D, Sullivan, J

A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. by Larsson, M, Jin, X, Ramratnam, B, Ogg, G, Engelmayer, J, Demoitie, M, Mcmichael, A, Cox, W, Steinman, R, Nixon, D, Bhardwaj, N

An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. by Jin, X, Ogg, G, Bonhoeffer, S, Safrit, J, Vesanen, M, Bauer, D, Chen, D, Cao, Y, Demoitie, M, Zhang, L, Markowitz, M, Nixon, D, McMichael, A, Ho, D

High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections. by Jin, X, Demoitie, M, Donahoe, S, Ogg, G, Bonhoeffer, S, Kakimoto, WM, Gillespie, G, Moss, P, Dyer, W, Kurilla, MG, Riddell, SR, Downie, J, Sullivan, J, Mcmichael, A, Workman, C, Nixon, D

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. by Bejon, P, Lusingu, J, Olotu, A, Leach, A, Lievens, M, Vekemans, J, Mshamu, S, Lang, T, Gould, J, Dubois, M, Demoitié, M, Stallaert, J, Vansadia, P, Carter, T, Njuguna, P, Awuondo, K, Malabeja, A, Abdul, O, Gesase, S, Mturi, N, Drakeley, C, Savarese, B, Villafana, T, Ballou, W, Cohen, J

PHASE IIB, RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE EFFICACY, SAFETY AND IMMUNOGENICITY OF THE CANDIDATE MALARIA VACCINE RTS,S/AS01 IN KENYAN AND TANZANIAN CHILDREN by Bejon, P, Lusingu, J, Olotu, A, Leach, A, Lievens, M, Vekemans, J, Msham, S, Lang, T, Gould, J, Dubois, M, Demoitie, M, Vansadia, P, Carter, T, Njuguna, P, Kawuondo, K, Gesase, S, Drakeley, C, Savarese, B, Villafana, T, Ballou, W, Cohen, J, Riley, E, Lemnge, M, Marsh, K, von Seidlein, L